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Alterations in DNA methylation are early, but not initial,
events in ovarian tumorigenesis
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Summary We compared global levels of DNA methylation as well as methylation of a specific locus (MyoDl) in ovarian cystadenomas,
ovarian tumours of low malignant potential (LMP) and ovarian carcinomas to investigate the association between changes in DNA
methylation and ovarian tumour development. As we realized that cystadenomas showed different methylation patterns from both LMP
tumours and carcinomas, we verified their monoclonal origin as a means of confirming their true neoplastic nature. High-pressure liquid
chromatographic (HPLC) analyses showed that global methylation levels in LMP tumours and carcinomas were 21% and 25% lower than in
cystadenomas respectively (P= 0.0001 by one-way variance analysis). Changes in the methylation status of the MyoDl locus were not seen
in any of ten cystadenomas analysed but were present in five of ten LMP tumours and in five of ten carcinomas (P = 0.03). These findings
suggest that alterations in DNA methylation are absent (or at least not as extensive) in ovarian cystadenomas, but are present in LMP
tumours, the phenotypic features of which are intermediate between those of benign and malignant ovarian tumours. The results also
emphasize the merit of distinguishing ovarian LMP tumours from cystadenomas, in spite of their similar clinical characteristics.
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The phenotypic characteristics of every living cell are determined
primarily by the nucleotide sequence of their respective genome.
However, several epigenetic mechanisms may modulate genomic
activity and further contribute to phenotypic variation. Methylation
of the 5-position of cytosine, which is the only known covalent
modification of mammalian DNA, may be an important example
[see Bird (1992) for review]. This modification is essential for
mammalian development because mice that have a reduced ability
to methylate their DNA owing to mutations in the methyltrans-
ferase gene die early during embryogenesis (Li et al, 1992).
Patterns of methylation are heritable, undergo characteristic
changes during embryological development and are tissue specific
(Bird, 1986). Alterations in DNA methylation can be correlated
with a variety of processes, including control of gene expression
(Ehrlich and Wang, 1981; Keshetet al, 1985),X-chromosomal inac-
tivation (Mohandas et al, 1981), chromatin structure (Antequera et
al, 1990), genomic imprinting (Li et al, 1993) and timing ofreplica-
tion (Selig et al, 1988). Evidence is also growing that alterations in
DNA methylation play a major role in the development of human
cancers (Spruck et al, 1993; Laird and Jaenisch, 1994). Indeed,
changes in genomic methylation, either focal or global, are one of
the most consistent findings in human cancers (Gama-Sosa et al,
1983; Makos et al, 1993; Vertino et al, 1993) and an epigenetic
mechanism was proposed whereby such changes may contribute to
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neoplastic transformation by changing the expression patterns of
genes involved in growth control (Antequera etal, 1990; Jones etal,
1990). For example, hypomethylation of several proto-oncogenes
including c-myc (Munzel et al, 1991; Sharrard et al, 1992), ras
(Bhaveetal, 1988),raf(Ray etal, 1994),bcl-2 (Hanadaetal, 1993),
erb-Al (Lipsanen et al, 1988), and c-fins (Felgner et al, 1991) was
reported in various types of cancerous tissues. In addition, expres-
sion of several tumour-suppressor genes including p16/CDKN2
(Merlo et al, 1995; Gonzalez-Zulueta et al, 1995; Herman et al,
1994), retinoblastoma (Greger et al, 1989; Sakai et al, 1991) and
von Hippel Lindau gene (Herman et al, 1994) can be turned offby
methylation.
It is of interest to know the time point at which changes in DNA
methylation occur during tumour development. This is not only
important for our understanding of the molecular mechanisms
underlying tumorigenesis, but is also relevant for the potential use
of methylation-interfering drugs in cancer chemotherapy. This
issue was raised more than a decade ago for colorectal tumours
(Feinberg and Vogelstein, 1983; Goelz et al, 1985). Global hypo-
methylation ofbenign colorectal polyps was found to be similar to
that present in colorectal carcinomas in these studies, suggesting
that such changes precede the appearance ofthe malignant pheno-
type and are thus involved in early steps of neoplastic transforma-
tion (Feinberg et al, 1988; Fearon and Vogelstein, 1990). In
contrast, Gama-Sosa et al (1983) studied over 100 samples from a
large variety of different tumour subtypes, including benign neo-
plasms, and found that hypermethylation was a general feature of
malignancy. More recently, Nelkin et al (1991) found methylation
changes to be associated with the accelerated but not the chronic
phase of chronic myelogenous leukaemia, suggesting a role for
DNA methylation in the later stages ofthis particular tumour.
We used the ovarian model of tumour development to further
examine the association between alterations in DNA methylation
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and specific stages of tumorigenesis. Like colorectal tumours,
ovarian epithelial tumours are subdivided into benign (cystade-
nomas) and malignant (carcinomas) categories. In contrast to the
benign colorectal tumours that are often regarded as premalignant
lesions with a high tendency to progress to carcinomas, the benign
ovarian lesions appear more stable and much less likely to undergo
such progression. These lesions are therefore presumably more
homogeneous as a resultofthis apparent stability. The attraction of
the ovarian model is further enhanced by the fact that these
tumours also include a third category, called tumours of low
malignant potential (LMP), which are intermediate between
cystadenomas and carcinomas and, like the benign tumours, are
stable over time.
We examined and compared the levels of DNA methylation in
ovarian cystadenomas, LMP tumours and carcinomas in the
present manuscript. We reasoned that cystadenomas and LMP
tumours could be regarded as early steps ofmalignant transforma-
tion and we therefore sought to determine which step, if any, was
associated with DNA methylation changes. We also reasoned that
these experiments could provide us with an opportunity to
examine whether cystadenomas and LMP tumours are mechanisti-
cally similar or not, as the merit of classifying these two tumour
subtypes into separate categories is currently the subject of much
debate among pathologists (Kurman and Trimble, 1993). The
degree ofglobal DNA methylation in ovarian cystadenomas, LMP
tumours and carcinomas was compared using high-pressure liquid
chromatography (HPLC). We also examined the extent of methy-
lation of a specific gene, called MyoDl in each tumour type. The
latter gene was selected for two reasons. First, changes in the
patterns of methylation of MyoDl have been reported in various
tumour types (Rideout et al, 1994). We speculated that similar
changes may be present in ovarian tumours. Second, in contrast to
global levels of DNA methylation, which are decreased in most
neoplastic tumours (Gama-Sosa et al, 1983), MyoDl methylation
is increased in some malignant tumours (Rideout et al, 1994). We
were interested to know ifchanges leading to such hypermethyla-
tion of specific genes occurred at the same stages of ovarian
tumorigenesis as those leading to global hypomethylation. As we
realized that differences in DNA methylation patterns distin-
guished carcinomas and LMP tumours from cystadenomas, we
also sought to verify that ovarian cystadenomas are authentic
neoplasms and not hyperplastic conditions in orderto better under-
stand the significance of DNA methylation differences between
cystadenomas and other subtypes ofovarian epithelial tumours.
MATERIALS AND METHODS
Source and processing of tissue specimens
Tumour specimens were obtained fresh from the operating rooms
of either the USC/Norris Comprehensive Cancer Center or the
Women's Hospital ofthe Los Angeles County Medical Center and
frozen immediately. All tissues were obtained in compliance with
the rules ofthe Institutional Tissue Committee at the University of
Southern California and after approval was obtained from that
committee. Diagnostic verification of each case was done by one
of us (LD), who is a surgical pathologist familiar with ovarian
tumour histopathology. Histological sections of all frozen carci-
noma and LMP tumour samples were examined before DNA
extraction in order to confirm the presence oftumour tissue and to
rule out the presence of unacceptable amounts of non-neoplastic
stroma. For cystadenomas, the inner linings ofthe neoplastic cysts
were scraped with scalpel blades in orderto separate the neoplastic
cells from underlying cyst walls. Analysis of cells recovered in
such scrapings by flow cytometry revealed that over 99% stained
positively with anti-keratin monoclonal antibodies and were there-
fore of epithelial origin (not shown). DNA was extracted from
each tissue sample as described previously (Zheng et al, 1995).
High-pressure liquid-chromatography
DNA samples were digested by nuclease P1 (Boehringer
Mannheim, Indianapolis, IN, USA) and alkaline phosphatase
(Promega, Madison, WI, USA) for 4 h at 37°C (Gehrke et al,
1984). Samples were centrifuged, and 25- to 200-p1 aliquots of
the supernatants were injected directly into a HPLC apparatus
(purchased from Waters,Milford,MA,USA),equipped with a 440
Absorbance Detector and a 10 cm Brownlee RP-18 column
guarded by a Brownlee Aquaphore ODS precolumn. A solution
containing 50 mM sodium dihydrogen phosphate, pH 4.0 and
2.5% methanol was used as mobile phase. The flow rate was set
at 1 ml min-, and the absorbance was monitored at 254 nm.
Retention times were 6 min for deoxycytosine, 7.4 min for 5-
methyldeoxycytosine, 9 min for deoxythymidine, 10.5 min for
deoxyguanosine, and 29 min for deoxyadenosine under those
conditions. The purity of each peak was verified by variations of
mobile phase pH and methanol concentrations. Standard deoxynu-
cleosides were obtained from Sigma (St Louis, MO, USA).
Southern blotting analysis
An aliquot of 10 gg of each DNA sample was digested with
either the methylation-sensitive HpaII or the methylation-
insensitive MspI restriction endonuclease following manufac-
turer's (Boehringer-Mannheim) recommendations. The digested
DNA samples were electrophoresed on 1% agarose andtransferred
to Zetabind nylon membranes (BioRad, Richmond, CA, USA) as
described previously (Ehlen and Dubeau, 1990). The membranes
were hybridized to a radiolabelled 800-base pair cDNA probe for
the MyoDI locus obtained from Professor HH Arnold (Braun et al,
1994) ofthe University ofBraunschweig (Germany), andautoradi-
ographed. Conditions for hybridization and probe labelling were
described previously (Ehlen and Dubeau, 1990).
Analysis of X-chromosome Inactivation
An aliquot of 1 p1 of DNA isolated from either the patient's blood
or from the epithelial cells lining ovarian cysts was incubated
overnight in the presence or absence of5 units ofHpaII restriction
endonuclease in a total volume of 10 pl. Polymerase chain reac-
tion (PCR) reagents were then added to each tube, bringing the
final volume to 100 gl. Sense and antisense primers were 5'-
TGCGCGAAGTGATCCAGAAC-3' and 5'-CTTGGGGAGAAC-
CATCCTCA-3' respectively. These primers flank a trinucleotide
repeat polymorphism in exon 1 of the androgen receptor gene
(Sleddens et al, 1992) as well as two HpaII restriction endonu-
clease sites located within 100 bases of this polymorphism (Allen
et al, 1992). Conditions for the PCR reactions were as follows:
940C for 30 s,55°C for 30 s and 720C for 30 s. PCR was continued
for 25 cycles. An aliquot of 1 pl from each reaction was then trans-
ferred to a new PCR mix and reamplified with nested primers
in a 25-p1 reaction volume containing 1 pCi of 2-10 Ci mmol-'
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Table 1 5-Methylcytosine content in normal and neoplastic ovaries
Tissue source 5-Methylcytosine (mol %)a nb
Cystadenomas 0.97 ± 0.08 7
LMP tumours 0.80 ± 0.07 8
Carcinomas 0.73 ± 0.08 10
two-sided P= 0.0001c
aMean ± standard deviation. bNumber of specimens analysed. cThe one-way
variance method was used to compare levels of 5-methylcytosine between
the three groups of ovarian tumours. Subsequent pairwise comparisons
showed statistically significant differences between cystadenomas vs LMP
tumours and cystadenomas vscarcinomas. No differences were seen
between LMP tumours vscarcinomas.
[a-32P]dCTP (ICN Radiochemicals, Irvine, CA, USA). Primers
for this reamplification reaction were: 5'-GAAGATTCAGC-
CAAGCTCAA-3' and 5'-TGAAGGTTGCTGTTCCTCAT-3'. The
radiolabelled products were electrophoresed on 6% polyacry-
lamide gels under denaturing conditions and autoradiographed.
Statistical analysis
The analysis ofvariance method was used to compare 5-methylcy-
tosine levels in cystadenomas, LMP tumours and carcinomas
(Dixon and Massey, 1969). Fisher's exact test (Dixon and Massey,
1969) was used to compare the proportions of tumours with
methylation changes in the cystadenoma group vs the group of
LMP tumours and carcinomas. All P-values quoted are two-sided.
RESULTS
Global levels of methylation in ovarian cystadenomas,
LMP tumours and carcinomas
We measured the global levels of methylation in DNA samples
obtained from seven ovarian cystadenomas, eight LMP tumours
and ten carcinomas in order to determine if these different tumour
subtypes, which can be regarded as representing different degrees
ofneoplastic transformation, could be distinguished on the basis of
such measurements. DNA isolated from the various ovarian
tumours was digested to single nucleosides and analysed by HPLC
as explained in Materials and methods. This approach gives an
accurate determination of the percentage of methylated cytosine
residues, as incompletely digested products or impurities are
readily identified as extra peaks in the chromatogram. Mean global
levels of DNA methylation showed significant differences (P =
0.0001) among the three ovarian tumour subtypes (Table 1).
Subsequent pairwise comparisons revealed significant differences
in mean levels of 5-methylcytosine between cystadenomas and
LMP tumours and between cystadenomas and carcinomas. Mean
levels in LMP tumours and carcinomas were 79% and 75% respec-
tively of the mean in cystadenomas. There was no difference in
mean levels of 5-methylcytosine content between LMP tumours
and carcinomas (Table 1).
The above seven cystadenomas included two tumours with
serous differentiation and five mucinous tumours. Five ofthe eight
LMP tumours were serous whereas the remaining three were
mucinous. Eight of the ten carcinomas were serous whereas two
were endometrioid. Accurate comparisons between these different
histological subtypes within each category is not possible because
Case number
Enzyme
1078 -
3 4 6 12 50
M H M H M H M H M H
872 -
603 -
Case number 1 7 31 39 40
Enzyme M H M H M H M H M H
1078 -
872 -
603-
Figure 1 Methylation of the MyoDl locus in ovarian cystadenomas and LMP tumours. DNA obtained from either cystadenomas or LMP tumours was digested
with Mspl (M) or Hpall (H) restriction endonucleases and analysed by Southern blotting using a radiolabelled probe for the MyoDl locus. The figure shows
autoradiographs of representative Southern blots. The numbers on the left of each autoradiograph indicate fragment lengths (base pairs)
British Journal ofCancer (1997) 75(3), 396-402
Cystadenomas
LMP tumours
0 Cancer Research Campaign 1997DNA methylation in ovarian tumours 399
Table 2 Methylation of Hpall restriction endonuclease sites in normal and neoplastic ovarian tissues
Tissue source Cases with no methylation Cases with methylation Proportion of cases with methylation
Normal ovaries 6,14,17, 18, 19 None 0/5
Cystadenomas 3, 4, 5, 6, 11, 12, 15, 37, 47, 50 None 0/1Oa
LMP tumors 1, 6, 7,10, 11 3,5,31,39,40 5/10a
Carcinomas 31, 35, 40, 67, 69 41, 43, 47, 61, 64 5/10
aThe proportion of cystadenomas with methylation was significantly different from that of LMP tumors (two-sided P = 0.03).
Tumour histological subtypes: serous cystadenomas (nos 5, 6, 11, 37), mucinous cystadenomas (nos 3, 4, 12, 15, 50), simple cystadenoma (no. 47), serous
LMP tumours (nos 1, 3, 7, 10, 39, 40), mucinous LMP tumours (nos 5, 6, 11, 31), serous carcinomas (nos 31, 35, 41, 43, 47, 61, 67, 69), endometrioid
carcinomas (40, 64).
*- 10
c
BT BT
BT BT
Figure 2 Clonal origin of ovarian cystadenomas. DNA obtained from either
blood (B) or tumour (T) samples of a patient with a large serous ovarian
cystadenoma was either left undigested or digested with the Hpall restriction
endonuclease. Each sample was then amplified enzymatically using primers
flanking a trinucleotide repeat polymorphism in the first exon of the androgen
receptor gene as well as two Hpall sites located within 100 base pairs of this
polymorphism. The radiolabelled PCR products were electrophoresed on 6%
agarose under denaturing conditions and autoradiographed
ofthe small number oftumours examined. However, there were no
apparent associations between DNA methylation levels and either
serous, mucinous, or endometrioid differentiation.
We also measured 5-methylcytosine levels in four samples of
normal ovarian tissues. Such levels were significantly higher than
in cystadenomas (1.51 mol%, standard deviation 0.19%). The
significance of these differences between normal ovarian tissues
and cystadenomas, however, is unclear (see Discussion).
Methylation of the MyoDl locus in ovarian
cystadenomas, LMP tumours and carcinomas
The above results suggest that global changes in DNA methylation
in ovarian epithelial tumours are most extensive in LMP tumours
and carcinomas. We therefore assessed levels ofmethylation ofthe
MyoDl locus in such tumours in order to determine whether
methylation changes also correlate with the degree of neoplastic
transformation at the level of individual genes. Interestingly,
studies of MyoDl methylation in other tumour models suggested
that there is increased methylation at this locus in malignant
tumours (Rideout et al, 1994), reflecting the fact that both, local
hypo- and hypermethylation changes occur during tumorigenesis.
We therefore sought to determine if changes affecting the MyoDl
locus occur at the same stage oftumorigenesis as those responsible
for generalized genomic hypomethylation. We took advantage of
the fact that two potential methylation sites in the MyoDI locus are
within recognition sequences for the methylation-sensitive HpaII
restriction endonuclease. Methylation ofthese two sites has previ-
ously been associated with malignant transformation (Rideout et
al, 1994). DNA from the various tumour samples was digested
either with this enzyme or with the MspI endonuclease. The latter
enzyme recognizes the same sequence as HpaII but is methylation
insensitive. The digested samples were electrophoresed on 1%
agarose and analysed by Southern blotting using a cDNA probe
forMyoD1.
The results for selected cystadenomas and LMP tumours are
shown in Figure 1. DNA digested with MspI produced a single
fragment of 603 base pairs in each case. The same fragment was
obtained after digestion of cystadenoma DNA with HpaII. Thus,
the HpaII sites at the MyoDl locus were totally unmethylated in
these tumours because the presence ofmethylated cytosines would
have prevented cleavage by this enzyme and resulted in fragments
of larger sizes. Such larger fragments were found in three of the
five LMP tumours illustrated in the figure.
The above approach was used to examine the methylation status
of HpaII sites in the MyoD1 locus in five normal ovaries, ten
cystadenomas, ten LMP tumours and ten carcinomas. The results
are shown in Table 2. None of the five normal ovarian tissue
samples showed methylation of these sites. Likewise, DNA
methylation was not detected in any of the ten cystadenomas
examined. In contrast, five ofthe ten LMP tumours and five ofthe
ten carcinomas showed methylation of either one or both HpaII
sites (Table 2). We compared the proportion of cystadenomas
showing methylation changes with that of LMP tumours and
found the difference to be statistically significant (P = 0.03).
Ovarian cystadenomas are authentic neoplasms
We examined eight ovarian cystadenomas ranging in size from 3
to 12 cm and determined whether these tumours were of mono-
clonal origin or not. Our intention was to better understand the
significance of the distribution of alterations in DNA methylation
in ovarian tumours, as it was unclearto us ifovarian cystadenomas
represented neoplastic or hyperplastic lesions (see Discussion).
Monoclonality is a feature of neoplasia whereas polyclonality is
usually indicative ofnon-neoplastic disorders such as hyperplasia.
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We therefore used an approach first developed by Vogelstein et al
(1985) to examine the monoclonal origin of the above eight
cystadenomas. This approach is based on the fact that all tumour
cells within a given tumour mass show inactivation of the same
allele of the X chromosome if the tumour originated from a single
cell (monoclonal). In contrast, polyclonal cell populations show
random inactivation of one or the other X chromosome allele.
DNA from each of the above tumour samples as well as from each
patient's blood was either undigested or digested with the HpaII
restriction enzyme. This enzyme is methylation sensitive and
therefore does not cleave DNA at methylated sites. The digested
fragments were amplified enzymatically using primers flanking a
trinucleotide repeat polymorphism in the androgen receptor gene
on chromosome Xq (Sleddens et al, 1992). These primers also
flanked two sites for the HpaII restriction endonuclease that are
adjacent to the trinucleotide repeat. At least one of these sites is
unmethylated if it is located on an active allele of the X chromo-
some whereas both sites are invariably methylated if they are
located on an inactive allele (Allen et al, 1992). Thus, only
sequences from inactive X chromosome alleles are amplifiable
using the above set of primers because sequences from active
alleles, which are sensitive to HpaII digestion, are cleaved during
the prior digestion with this enzyme.
The results of a representative experiment are shown in Figure
2. Undigested DNA from either blood or tumour samples showed
fragments of two different sizes after enzymatic amplification with
the above primers (Figure 2). These two fragments corresponded
to the two alleles of the androgen receptor gene in this patient.
Both alleles were also present in digested DNA from the patient's
blood. This indicates that an equal proportion of each allele was
resistant to HpaII digestion in this sample, confirming a polyclonal
origin. However, only one of the two alleles could be amplified in
digested tumour DNA, indicating that X inactivation affected this
allele exclusively in all tumour cells from this patient. Similar
results were obtained with all remaining seven cases examined
(not shown). We conclude that ovarian cystadenomas are mono-
clonal and are therefore true neoplasms.
DISCUSSION
The time at which alterations in DNA methylation take place
during tumour development is still not clear. Although such
changes are clearly associated with the malignant phenotype in a
large number of different tumour types (Gama-Sosa et al, 1983),
they are also found in some benign neoplasms such as colorectal
polyps (Goelz et al, 1985; Feinberg et al, 1988). Ovarian epithelial
tumours are a good model to address this question because there are
two well-defined subtypes of these tumours that do not fully
express the malignant phenotype (Cheng et al, 1996) and can there-
fore be regarded as different early stages of malignant transforma-
tion. The results of our experiments clearly show that DNA
methylation changes are present in both, ovarian LMP tumours and
carcinomas, lending further support to the idea advanced by Goelz
et al (1985) that such changes are early events in malignant trans-
formation. However, our results also show that global alterations in
genomic methylation are less extensive (and perhaps absent) in
cystadenomas, which are authentic (although benign) neoplasms
based on our demonstration oftheir monoclonal origin. Changes in
methylation of the MyoDl locus, which were similar in LMP
tumours and carcinomas, were likewise not detected in cystade-
nomas. We conclude that alterations in DNA methylation are early,
but not initial events in ovarian tumorigenesis because they occur in
LMP tumours, the phenotypic manifestations ofwhich are interme-
diate between fully malignant and clearly benign ovarian tumours.
The above results also emphasize the merit of subdividing the
non-invasive and non-metastatic subtypes of ovarian tumours into
cystadenomas and LMP tumours. This issue is the subject of much
debate among pathologists. Indeed, it has been argued that LMP
tumours (at least those showing serous differentiation) typically
behave as benign lesions clinically and should not therefore be
regarded as a separate disease entity (Kurman and Trimble, 1993).
However, our results suggest that such tumours (three of the five
LMP tumours with methylation changes at the MyoD1 locus were
of serous differentiation) may develop through different genetic
mechanisms from cystadenomas. This conclusion is also supported
by recent data from our laboratory (Cheng et al, 1996). The avail-
able evidence therefore supports the notion that LMP tumours are
mechanistically more complex than cystadenomas and strongly
argues in favour of maintaining the distinction between these two
variants of ovarian epithelial tumours, in spite of the fact that they
often show similar clinical behaviour.
We also observed substantial differences between levels of
methylation in cystadenomas and those present in normal ovarian
tissues. It is possible that these differences reflect methylation
changes associated with the development of ovarian cystade-
nomas. However, normal ovaries are made up of a variety of
different cell types including stromal cells, germ cells, follicular
cells, etc. These different cell types probably show significant
differences in their levels and patterns of DNA methylation
because of their widely different functions and spectra of gene
expression. Ovarian surface epithelial cells, which are the alleged
origin of ovarian epithelial tumours, account for less than 1I% of
the cell types present in normal ovarian tissue samples. Thus, we
favour the explanation that the observed differences between the
methylation levels of normal ovaries compared with ovarian
cystadenomas are due primarily to differences in the various cell
types present in those tissue samples.
A widely accepted theory stipulates that ovarian cystadenomas
arise from invaginations ofthe ovarian surface, resulting in entrap-
ment of the surface epithelial cells which, as they continue to
proliferate, form intra-ovarian cysts. If true, the initial steps in
cystadenoma development are not neoplastic and the above mecha-
nism could be compatible with a hyperplastic phenomenon. Indeed,
small (<1 cm) ovarian cysts are regarded as non-neoplastic by
convention. We considered the possibility that larger cysts were
also non-neoplastic because the differences in the methylation
levels ofcystadenomas compared to LMP tumours and carcinomas
suggest fundamentally different underlying mechanisms for these
tumour subtypes. We therefore determined whether cystadenomas
were monoclonal or polyclonal because most neoplasms are
thought to have a monoclonal origin whereas hyperplasias are
thought to be polyclonal. However, our finding that ovarian
cystadenomas are monoclonal provides strong support for their
alleged neoplastic nature and does not support a hyperplastic
origin. Thus, the clear differences in the DNA methylation levels of
LMP tumours or carcinomas when compared with cystadenomas
suggest that, although methylation changes are a general feature of
malignant neoplasms, such changes are not essential for neoplastic
transformation per se, at least in ovarian tumours.
It is not known if the above alterations in DNA methylation are
causes or consequences of ovarian carcinoma and LMP tumour
development. However, the fact that the expression of genes
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involved in growth control and tumorigenesis was reported to be
altered as a result of DNA methylation changes in tumours of
different histological types suggests that such alterations may
indeed play an active and important role in the establishment ofthe
malignant phenotype. Possibilities include the silencing of
tumour-suppressor genes or the increased expression of proto-
oncogenes (Balmain, 1995). Identification of specific genetic
targets for methylation changes in ovarian epithelial tumours may
not only lead to a better understanding of the molecular mecha-
nisms and determinants of their development, but may also facili-
tate the use and monitoring of methylation-targeting drugs in the
treatment ofovarian cancer patients.
ABBREVIATIONS
LMP, low malignant potential; HPLC, high-pressure liquid
chromatography.
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